NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report
IntroductionA 73-year-old Chinese woman with no smoking history was diagnosed with stage IV adenocarcinoma of the lung in August 2020, presenting with left chest pain and multiple lung lesions.Patient concernsThe patient experienced chest pain for 2 months before diagnosis. Initial CT scans revealed...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1571777/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849338262780379136 |
|---|---|
| author | Jielin Li Yunyun Shi Mengge Zheng Chenkang Yang Hong Gao Xiaoling Li |
| author_facet | Jielin Li Yunyun Shi Mengge Zheng Chenkang Yang Hong Gao Xiaoling Li |
| author_sort | Jielin Li |
| collection | DOAJ |
| description | IntroductionA 73-year-old Chinese woman with no smoking history was diagnosed with stage IV adenocarcinoma of the lung in August 2020, presenting with left chest pain and multiple lung lesions.Patient concernsThe patient experienced chest pain for 2 months before diagnosis. Initial CT scans revealed multiple lung nodules, enlarged lymph nodes, and pleural effusion.DiagnosisThe diagnosis was confirmed as advanced NSCLC the left upper lobe of the lung with specific genetic alterations, including EGFR 19del, EGFR amplification, and TPR-NTRK1 fusion, through molecular testing.InterventionsPrior treatments included the first-line therapy gefitinib (250 mg/day) administered from September 2020 to June 2021, targeting the EGFR 19del mutation, achieving a partial response (PR). The second-line therapy osimertinib (80 mg/day) was administered from July 2021 to January 2022, targeting EGFR 19del and T790M mutations, with a progression-free survival (PFS) of approximately 7 months. The third-line therapy almonertinib, another third-generation EGFR-TKI, was administered from January 2022 to March 2022, but the response was poor, leading to further progression. After identifying NTRK fusion and EGFR amplification, the patient was administered larotrectinib as third-line treatment. Prior treatments included targeted therapies and chemotherapy.OutcomesDespite multiple lines of targeted therapy, the patient experienced rapid disease progression at several points, highlighting the challenges in managing NSCLC with complex genetic alterations.ConclusionThis case underscores the importance of ongoing molecular testing and the potential need for combination therapies in managing advanced NSCLC with resistance to multiple targeted treatments. The current treatment with camrelizumab combined with chemotherapy shows promise, but further monitoring is necessary. |
| format | Article |
| id | doaj-art-2be8c4e4ec864e3bb23e77b1b68f0c13 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-2be8c4e4ec864e3bb23e77b1b68f0c132025-08-20T03:44:28ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-08-011610.3389/fphar.2025.15717771571777NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case reportJielin Li0Yunyun Shi1Mengge Zheng2Chenkang Yang3Hong Gao4Xiaoling Li5Department of Thoracic Internal Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, ChinaGenetron Health (Beijing) Co. Ltd., Beijing, ChinaGenetron Health (Beijing) Co. Ltd., Beijing, ChinaGenetron Health (Beijing) Co. Ltd., Beijing, ChinaDepartment of Thoracic Internal Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, ChinaDepartment of Thoracic Internal Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, ChinaIntroductionA 73-year-old Chinese woman with no smoking history was diagnosed with stage IV adenocarcinoma of the lung in August 2020, presenting with left chest pain and multiple lung lesions.Patient concernsThe patient experienced chest pain for 2 months before diagnosis. Initial CT scans revealed multiple lung nodules, enlarged lymph nodes, and pleural effusion.DiagnosisThe diagnosis was confirmed as advanced NSCLC the left upper lobe of the lung with specific genetic alterations, including EGFR 19del, EGFR amplification, and TPR-NTRK1 fusion, through molecular testing.InterventionsPrior treatments included the first-line therapy gefitinib (250 mg/day) administered from September 2020 to June 2021, targeting the EGFR 19del mutation, achieving a partial response (PR). The second-line therapy osimertinib (80 mg/day) was administered from July 2021 to January 2022, targeting EGFR 19del and T790M mutations, with a progression-free survival (PFS) of approximately 7 months. The third-line therapy almonertinib, another third-generation EGFR-TKI, was administered from January 2022 to March 2022, but the response was poor, leading to further progression. After identifying NTRK fusion and EGFR amplification, the patient was administered larotrectinib as third-line treatment. Prior treatments included targeted therapies and chemotherapy.OutcomesDespite multiple lines of targeted therapy, the patient experienced rapid disease progression at several points, highlighting the challenges in managing NSCLC with complex genetic alterations.ConclusionThis case underscores the importance of ongoing molecular testing and the potential need for combination therapies in managing advanced NSCLC with resistance to multiple targeted treatments. The current treatment with camrelizumab combined with chemotherapy shows promise, but further monitoring is necessary.https://www.frontiersin.org/articles/10.3389/fphar.2025.1571777/fullEGFR-mutated NSCLCNTRK-fusionlarotrectinibresistancecase report |
| spellingShingle | Jielin Li Yunyun Shi Mengge Zheng Chenkang Yang Hong Gao Xiaoling Li NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report Frontiers in Pharmacology EGFR-mutated NSCLC NTRK-fusion larotrectinib resistance case report |
| title | NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report |
| title_full | NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report |
| title_fullStr | NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report |
| title_full_unstemmed | NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report |
| title_short | NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report |
| title_sort | ntrk1 fusion as an acquired resistance mechanism in egfrex19 mutated nsclc a case report |
| topic | EGFR-mutated NSCLC NTRK-fusion larotrectinib resistance case report |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1571777/full |
| work_keys_str_mv | AT jielinli ntrk1fusionasanacquiredresistancemechanisminegfrex19mutatednsclcacasereport AT yunyunshi ntrk1fusionasanacquiredresistancemechanisminegfrex19mutatednsclcacasereport AT menggezheng ntrk1fusionasanacquiredresistancemechanisminegfrex19mutatednsclcacasereport AT chenkangyang ntrk1fusionasanacquiredresistancemechanisminegfrex19mutatednsclcacasereport AT honggao ntrk1fusionasanacquiredresistancemechanisminegfrex19mutatednsclcacasereport AT xiaolingli ntrk1fusionasanacquiredresistancemechanisminegfrex19mutatednsclcacasereport |